SEC Filings

Form 10-Q
VERASTEM, INC. filed this Form 10-Q on 05/09/2019
Document Outline
Entire Document (4158.7 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - FORWARD LOOKING STATEMENTS
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - Verastem, Inc.
Page 6 - Verastem, Inc.
Page 7 - Verastem, Inc.
Page 8 - Verastem, Inc.
Page 9 - Significant Accounting Policies
Page 10 - Product Revenue, Net
Page 11 - Exclusive Licenses of Intellectual Property -
Page 12 - N/A
Page 13 - Collaborative Arrangements
Page 14 - Recently Issued Accounting Standards Updates
Page 15 - Leases (Topic 842)LeasesLeases Leases (Topic 842): Targeted Improvements
Page 16 - Items Measured at Fair Value on a Recurring Basis
Page 17 - 5. Investments
Page 18 - 7. Intangible assets
Page 19 - 9. Product revenue reserves and allowances
Page 20 - 11. Long-term debt
Page 21 - 12. Convertible Senior Notes
Page 22 - 13. Stock based compensation
Page 23 - Restricted stock units (RSUs)
Page 24 - 14. Net loss per share
Page 25 - CSPC Pharmaceutical Group Limited (CSPC)
Page 26 - 16. Income taxes
Page 27 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 28 - CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Page 29 - N/A
Page 30 - Exclusive Licenses of Intellectual Property -
Page 31 - Collaborative Arrangements
Page 32 - Accounts Receivable, Net
Page 33 - Leases
Page 34 - Product revenue, net.
Page 35 - Interest income.
Page 36 - Financing activities.
Page 37 - License and collaboration agreements
Page 38 - Funding requirements
Page 39 - CONTRACTUAL OBLIGATIONS AND COMMITMENTS
Page 40 - Item 4. Controls and Procedures.
Page 41 - PART II OTHER INFORMATION
Page 42 - Item 6. Exhibits.
Page 43 - EXHIBIT INDEX
Page 44 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - Exhibit 31.1
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - Exhibit 31.2
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - Exhibit 32.1
Subdocument 5 - EX-32.2 - EX-32.2
Page 1 - Exhibit 32.2
Subdocument 6 - EX-99.1 - EX-99.1
Page 1 - Verastem Oncology Reports First Quarter 2019 Financial Results
Page 2 - Corporate and Financial
Page 3 - First Quarter 2019 Financial Results
Page 4 - About Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Page 5 - About Verastem Oncology
Page 6 - DRUG INTERACTIONS
Page 7 - References
Page 8 - Verastem, Inc.
Page 9 - Verastem, Inc.
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer